To include your compound in the COVID-19 Resource Center, submit it here.

Panel backs KemPharm analgesic, doubts abuse deterrence

FDA's Anesthetic and Analgesic Drug Products and Risk Management Advisory Committees voted 16-4

Read the full 138 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE